Top Ten most popular articles on Pharmafile.com this week
Moving into February,and the first weeks of Trump’s term, the US President has dominated the headlines in the industry as he has in mainstream news with his resonating intentions for the future of pharma, while a fresh scandal in the Chinese industry has taken the top spot.
Check out the stories our readers found most popular over the past week.
Discussions of pricing have remained consistent entering into 2017 and a major case has been brought against three of the largest producers of insulin.
Key figures in the Pakistani pharmaceutical industry are calling for review of the Drug Regulatory Authority of Pakistan (DRAP) over concerns it is not fit to streamline healthcare issues in the country.
A potential new treatment for opioid withdrawal has been found with an old drug, used to treat gout. The research could potentially lead to another tool in the arsenal of those fighting to stay the opioid crisis that is sweeping North America.
MSD has attempted to diffuse its own part in the drug pricing debate by releasing figures upon the levels of drug price increase.
Kevzara (sarilumab) has been awarded its first marketing approval for use in Canada.
An executive order signed by President Donald Trump on Monday has caused concern in the US pharma industry and beyond over its potential impact on the country’s regulatory system.
Amgen drug pair become first Humira biosimilars to win EU approval
Here at Pharmafile.com, we look back at the big mergers of the year just gone and see how things have developed for the companies involved since the deals were announced.
President Trump convened with a number of top pharma execs at the White House on Tuesday to discuss the key matters of drug pricing and the US regulatory process.
A worrying development has been discovered in China, as the dump of 53 tonnes of antibiotics has been linked to the rise of antibiotic resistant bacteria.
As the year winds to a close, excitement is rising around the efficacy and availability …
The top ten news stories this week focus on herd immunity, as the Director of …